BIOTECHNOLOGY VALUE FUND L P 4

What Happened
BVF Partners L.P. (part of a group of BVF entities reporting jointly) was reported as the recipient of a grant/award of 29,500 derivative shares in Olema Pharmaceuticals (OLMA) on June 18, 2026. The filing records the acquisition as an award (code A) at $0.00 per share (reported value $0). The Form 4 was filed on June 23, 2026.

Key Details

• Transaction date: 2026-06-18 — Award/Grant of 29,500 derivative shares at $0.00 (Acquired).
• Filing date: 2026-06-23 (Form 4 accession 0000921895-26-001653).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Vesting/terms: Footnote F9 indicates these shares (or related option) vest in 12 equal monthly installments beginning June 18, 2026, subject to continuous service; they vest in full by the next annual meeting if not otherwise fully vested.
• Reporting structure & disclaimers: The Form 4 is filed jointly by multiple BVF entities and Mark N. Lampert (F1–F5). They state membership in a Section 13(d) group and disclaim beneficial ownership except to the extent of pecuniary interest. Footnote F7 notes Gorjan Hrustanovic (an Olema director and member of Partners) has agreed to transfer any economic benefit from these securities to Partners, which is why the BVF group reports this award.

Context

• This was an award/derivative grant (not an open-market purchase or sale). That means it’s an acquisition of derivative rights (likely stock options or RSUs per the vesting language), not an immediate cash investment or liquidation.
• Because the filing is by an institutional group with disclaimers and an arrangement with a director to transfer economic benefit, the report indicates institutional/affiliate economic interest rather than direct personal trading by a single executive.
• No inference about future stock performance should be made solely from this award; it reflects compensation/arrangement terms and potential future ownership as vesting and any exercise occur.